Press Releases

BioIVT Joins the Foundation for the National Institutes of Health Biomarkers Consortium

By Lauren Vagnone | March 25, 2019

BioIVT Joins the Foundation for the National Institutes of Health Biomarkers Consortium

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium.Read more

BioIVT Webinar to Discuss Ethical and Regulatory Issues Regarding Use of Human Biospecimens in Life Sciences Research in the UK and EU

By Lauren Vagnone | March 18, 2019

Ethical and Regulatory Issues Regarding Use of Human Biospecimens in Life Sciences Research in the UK and EU

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be co-hosting a one-hour webinar entitled “Gaining Clarity: Unique Considerations for the Ethical and Regulatory Use of Human Biospecimens in the European Union (EU) and United Kingdom (UK)” at 8 a.m. EST on Mar. 19.
Read more

BioIVT Launches Its XPRESSWAY® Profile Safety Package, a Gene Expression Reference Guide Designed to Improve Drug Safety Analyses

By Lauren Vagnone | March 6, 2019

BioIVT Launches Its XPRESSWAY® Profile Safety Package, a Gene Expression Reference Guide Designed to Improve Drug Safety Analyses

This new product will help pharmaceutical companies to assess drug safety risks, inform go/no-go decisions in lead selection, and expedite drug discovery programs.
Read more

BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity

By Lauren Vagnone | November 5, 2018

BioIVT Acquires Biological Specialty Corporation, Adds Donor Centers and Increases Its Immune Cell Capacity

Acquisition increases BioIVT’s supply of leukopaks, plasma, and sera, and enhances its ability to support the in vitro diagnostic market.

Read more

BioIVT Appoints Alan Findlater as Chief Commercial Officer

By Lauren Vagnone | October 25, 2018

BioIVT Appoints Alan Findlater as Chief Commercial Officer

BioIVT is expanding its global commercial capabilities in response to growing demand for its biospecimens and specialized research services.

Read more

BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services

By Lauren Vagnone | October 16, 2018

BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services

QMS, Master Control will help to ensure consistent document tracking and training across all BioIVT sites and support the company’s rapid growth

Read more

BioIVT Acquires UK-based Clinical Trials Laboratory Services

By Lauren Vagnone | October 8, 2018

Acquiring this donor center and laboratory will enable BioIVT to ship high-quality blood products and blood-derived immune cells efficiently to researchers throughout Europe

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also has full-service cell processing capabilities on site.

Read more

BioIVT to Host the 2018 HEPATOPAC® User Group Meeting in Boston

By Lauren Vagnone | September 25, 2018

HEPATOPAC bioengineered micro-liver platforms are widely used for drug efficacy and safety research.

BioIVT, a leading provider of research models and services for drug development, today announced that it will be hosting the 2018 HEPATOPAC User Group Meeting (UGM) from 8:30 a.m. to 4:30 p.m. ET on Oct. 18 in Boston, MA.

Read more

BioIVT Publishes New Research On the Mechanisms Underlying the C-DILI Assay

By Lauren Vagnone | September 10, 2018

The C-DILI™ Assay is a highly effective tool for assessing cholestatic hepatotoxicity risk of promising new drug candidates.

BioIVT, a leading provider of research models and services for drug development, today announced its research into the mechanisms involved in cholestatic drug-induced liver injury (DILI) has been published in Applied In Vitro Toxicology.

Read more

BioIVT Launches Dissociated Tumor Cell (DTC) Product Line to Advance Oncology Research

By Lauren Vagnone | September 6, 2018

DTCs are primary cancer cells that are prepared with minimal manipulation and closely mimic tumor behavior.

BioIVT, a leading provider of research models and services for drug development, today announced the addition of a dissociated tumor cell (DTC) product line to its immunology portfolio.

Read more